Catalyst Pharmaceuticals Files 8-K

TL;DR

Catalyst Pharma filed an 8-K on 8/25/25 with corporate updates.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on August 25, 2025, reporting on other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). It also lists its principal executive offices in Coral Gables, Florida.

Why It Matters

This 8-K filing provides an update on Catalyst Pharmaceuticals' corporate information and financial reporting, which is important for investors to stay informed about the company's structure and operational details.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.

Key Numbers

• 001-33057 — Commission File Number (Identifies the company's SEC filing history.)
• 76-0837053 — I.R.S. Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — Registrant
• August 25, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• Coral Gables, Florida (location) — Principal executive offices

FAQ

From the Filing

0001193125-25-187733.txt : 20250825 0001193125-25-187733.hdr.sgml : 20250825 20250825163016 ACCESSION NUMBER: 0001193125-25-187733 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250825 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250825 DATE AS OF CHANGE: 20250825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 251251341 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d915025d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-08-25 2025-08-25     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 25, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) 355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On August 25, 2025, the Company issued a press release announcing that it and its licensor, SERB S.A. (“SERB”) have entered into a settlement agreement (“Agreement”) with Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”). This Agreement resolves the patent litigation brought by the Company and SERB in response to Lupin’s Abbr